The Director, US Obesity – Pre-Launch will support development and execution of the US pre-launch commercial and marketing strategy for Pfizer’s obesity portfolio. This role focuses on asset-level execution, translating early insights into actionable marketing plans, and ensuring alignment with cross-functional partners and global guidance.
As assets progress through late-stage development, this role will play a key part in supporting the translation of clinical data, competitive signals, and market insights into clear US commercial implications, product positioning, and early go-to-market readiness plans. The focus is on executional excellence and disciplined strategic thinking—connecting evidence, insights, and customer needs into actionable recommendations that support launch planning.
Operating within a highly matrixed environment, the Director must navigate ambiguity, collaborate effectively across cross-functional partners, and balance early brand-building needs with near-term launch milestones. This role is essential in ensuring that US launch plans are well-aligned, insight-driven, and designed to position Pfizer’s obesity assets for commercial impact in the US market.